

PACIFIC EDGE 2016 ANNUAL MEETING RESULTS

Pacific Edge held its Annual Meeting in Dunedin on 25 August 2016, updating shareholders on the milestones achieved in the past year and its positive progress in the year to date.

Incoming Chairman Chris Gallaher commented that Pacific Edge was an exciting company with world leading products and staffed by talented people committed to improving health outcomes and delivering value for shareholders.

“Pacific Edge has positioned itself well to win in the world’s largest healthcare market, the USA, and it’s gaining good traction in other markets. The potential to create shareholder value is enormous. The task now for the Board and management team is to deliver on that potential.”

Chris thanked retiring Chairman, Chris Swann, for his contributions to the company over the 11 years of his tenure.

“During his time, the company has grown from a medical research organisation to an international business making waves in the global healthcare market. Pacific Edge is leading the way in molecular diagnostics tests for bladder cancer patients, and we are now seeing growing acceptance and demand for our easy to use, accurate and cost effective Cxbladder tests. The company has undertaken large scale clinical trials with very positive results; has identified an effective commercial pathway to bring our products to market; and has built a strong platform on which our business can continue to grow.”

CEO of Pacific Edge, David Darling, updated shareholders on progress in the year to date, citing the recently announced coverage from a private insurance provider as an example of the traction Cxbladder is gaining as a cost efficient, accurate and easy to use bladder cancer diagnostic.

“The opportunity for our company is huge. We are well ahead of any potential competitors in terms of trial and acceptance of our technology, the development of a suite of products, and clinical validation. While we are still in the early stages of our journey, we are working hard to ensure our suite of products are the preferred choice for urologists and large healthcare organisations.

“We have a well-considered plan of action for the year and are already making progress against our objectives. We anticipate another year of growing returns as we work towards our goal of providing a ‘one stop shop’ of high performance Cxbladder products for urologists.”

Shareholders voted in favour of all resolutions at the 2016 Annual Meeting.

Resolution	For	Against	Abstain
Re-election of Mr David Band	129,182,501 85.13%	22,568,365 14.87%	359,331
Election of Mr David Levison	129,248,797 85.17%	22,511,613 14.83%	349,787
Election of Mr Chris Gallaher	129,217,341 85.15%	22,537,913 14.85%	354,943
Authorise Directors to fix the auditors’ remuneration	151,738,582 99.98%	28,888 0.02%	342,727

Pursuant to NZSX Listing Rule 3.3.2, Pacific Edge has determined that the following Directors are independent, as defined in NZSX Listing Rule 1.6.1:

- Chris Gallaher (Independent Chairman)
- David Band
- David Levison
- Anatole Masfen
- Bryan Williams

The following Directors are not Independent Directors due to a Disqualifying Relationship as defined in NZSX Listing Rule 1.6.1: David Darling: An executive of Pacific Edge.

A copy of the annual meeting presentation and speeches is available on the company website www.pacifedge.co.nz

ENDS

For more information contact:

David Darling, Chief Executive Officer, Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacifedge.co.nz www.pacifedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to www.cxbladder.com for more information.